Penn Medicine Provider
Jennifer Elizabeth Cohn, MD, MPH
Sees patients age 18 and up
Make an appointmentCall 800-789-7366

About me

  • Clinical Associate Professor of Medicine (Infectious Diseases)

I am the Senior Director of Innovation at the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and an infectious disease physician with a focus on HIV, TB and viral hepatitis. At EGPAF, I lead the Innovation and New Technology team in identifying promising innovations and developing and implementing innovative projects and programs. I am an assistant clinical professor of Infectious Diseases at the University of Pennsylvania School of Medicine and has provided clinical care to people living with HIV, HCV and TB in the US and Kenya.

I received my MD and infectious diseases sub-specialty training at University of Pennsylvania School of Medicine and my masters in public health (MPH) at Johns Hopkins University. I have served on national HIV treatment and care advisory committees in Kenya, international advisory groups on TB, HIV and viral hepatitis and have participated in WHO guidelines groups. I am published in peer-reviewed journals including Science, the Lancet, PLoS Medicine and JAIDS.

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Hospital of the University of Pennsylvania

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Cohn is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Lemaire JF, Cohn J, Kakayeva S, et al. Improving TB detection among children in routine clinical care through intensified case finding in facility-based child health entry points and decentralized management: A before-and-after study in Nine Sub-Saharan African Countries , PLOS Glob Public Health, 5(4): 2024

Bamford A, Masini T, Williams P, Sharland M, Gigante V, Dixit D, Sati H, Huttner B, Bin Nisar Y, Cappello B, Were W, Cohn J, Penazzato M; PADO-antibiotics participants. Tackling the threat of antimicrobial resistance in neonates and children: outcomes from the first WHO-convened Paediatric Drug Optimisation exercise for antibiotics , Lancet Child Adolesc Health. : 2024

Tchakounte Youngui B, Atwine D, Otai D, Vasiliu A, Ssekyanzi B, Sih C, Kana R, Arinaitwe R, Cuer B, Simo L, Okello R, Tchendjou P, Casenghi M, Kuate AK, Turyahabwe S, Cohn J, Bonnet M, Tchounga BK; CONTACT Study Group. Integration of HIV Testing in a Community Intervention for Tuberculosis Screening Among Household Contacts of Patients with Tuberculosis in Cameroon and Uganda , J Acquir Immune Defic Syndr.: 2024

da Costa R, Kothari K, Valmont T, Srinivasan S, Cohn J, Franceschi F, Hawser S. In vitro activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa (CRPA) clinical isolates from countries with high CRPA incidence, 2019-2022. , ESCMID Global. Barcelona, Spain. 2024: 2024

Cohn J, Balasegaram M, Srinivasan H, Menghaney L, Mpundu M, Waning B, Alimi Y. Improving equitable access for effective antibacterial: an ecosystem approach , Clin Microbiol Infect.: 2024

Aitcheson N, Sacks E, Nyamundaya TH, Muchuchuti C, Cohn J. The Cascade of Care for Early Infant Diagnosis in Zimbabwe: Point of Care HIV Testing at Birth and 6-8 Weeks , Pediatr Infect Dis J.: 2024

da Costa R, Kothari K, Valmont T, Srinivasan S, Cohn J, Franceschi F, Hawser S. In vitro activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates from countries with high CRAB incidence, 2019-2022. , ESCMID Global. Barcelona, Spain. 2024: 2024

Laxminarayan R, Impalli I, Rangarajan R, Cohn J, Ramjeet K, Trainor BW, Strathdee S, Sumpradit N, Berman D, Wertheim H, Outterson K, Srikantiah P, Theuretzbacher U. Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance , Lancet: 2024

Cohn J, Mendelson M, Kanj SS, Shafiq N, Boszczowski I, Laxminarayan R. Accelerating antibiotic access and stewardship: a new model to safeguard public health , Lancet Infect Dis.: 2024

da Costa R, Kothari K, Valmont T, Srinivasan S, Cohn J, Franceschi F, Hawser S. In vitro activity of cefiderocol against carbapenem-resistant Enterobacterales (CREs) clinical isolates from countries with high CRE incidence, 2019-2022. , ESCMID Global. Barcelona, Spain. 2024: 2024